CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%

AstraZeneca Gets FDA Approval for Breast Cancer Drug Truqap

By Business DeskAstraZeneca Gets FDA Approval for Breast Cancer Drug Truqap

AstraZeneca receives US FDA approval for Truqap (capivasertib), offering a new targeted oral treatment option for advanced HR-positive breast cancer.

A New Path for Targeted Oncology

The US Food and Drug Administration has granted official approval to AstraZeneca for its oral medication, Truqap, also known as capivasertib. This regulatory milestone provides a critical new therapeutic pathway for adults battling specific forms of breast cancer.

Targeting Advanced Cancer Progression

The approval focuses on patients who have limited options after their condition advances beyond standard care. Specifically, the drug is indicated for the following patient profiles:

  • Adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
  • Patients who have experienced disease progression following standard endocrine-based treatments.
  • Individuals identified with specific genetic mutations, namely PIK3CA, AKT1, or PTEN.

Strategic Expansion in Oncology

This development serves as a significant expansion of the AstraZeneca oncology portfolio. By introducing an oral targeted therapy for these specific genetic mutations, the company addresses a clear need for alternative options when initial treatment protocols fail. The approval reinforces the firm’s strategic focus on delivering specialized treatments within the competitive cancer care landscape.

Home/business/Article